Vaccinex LONG

16 juin 2021

Vacinex is a tiny company, $74 million market cap and approximately 29 million shares outstanding. They have beat street earnings expectations the past 2 quarters and they are working with Merck and the "keytruda" drug for an Alzheimer's "proof of concept" study. If the drug performs like it should, well, than you can guess where the price goes. 15% held by insiders, 36% held by institutions - this is critical, and only a 2% short position because everybody knows where it's going. It has a $7 price target and with any decent volume it will get to that number in a hurry. Thoughts? Comments? NASDAQ:VCNX

27 sept. 2021

Transaction en cours

I am still long this name at a higher price. Absolutely nothing but good news here and going forward. Trades a TINY amount daily. When the street comes for it - and they will - it will be too late.

3 nov. 2021

Transaction en cours

VCNX Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021 - stock is up 17% on big volume.

19 mai 2023

Transaction en cours

Symbol Date Shares Proceeds Transaction Details
VCNX 2023-05-15 6.712M $2,512,000.00 Stock Award(Grant) at $0.37 per share.
VCNX 2023-03-31 4.146M $1,700,000.00 Stock Award(Grant) at $0.41 per share.
VCNX 2022-11-23 3.779M $2,000,000.00 Stock Award(Grant) at $0.53 per share.
VCNX 2022-01-27 3.604M $3,297,000.00 Purchase at $0.92 per share.